We aimed to determine the incidence of symptomatic cardiotoxicity from capecitabine in patients with breast cancer and to identify risk factors. 1 0 obj stream Epub 2013 Apr 10.Curr Treat Options Oncol.

2018 May 11;38(1):22. doi: 10.1186/s40880-018-0292-1.Kosmas C, Kallistratos MS, Kopterides P, Syrios J, Skopelitis H, Mylonakis N, Karabelis A, Tsavaris N.J Cancer Res Clin Oncol.

doi: 10.1136/bcr-2017-220952. 2016 Jun;22(3):552-5. doi: 10.1177/1078155215579303. Proportion of patients with chest pain without ECG changes (n=10), chest pain with ECG changes but not acute myocardial infarction (n=1), acute myocardial infarction (n=2), arrhythmia (n=4), cardiac arrest (n=1), dyspnoea/incompensation (n=3) and other (n=1, with QT prolongation and right bundle branch block). We also describe a severe, reversible cardiac event that occurred in a 39‐year‐old woman, with no cardiac risk factors, treated with capecitabine for advanced breast cancer. Ann Oncol 2002; 13: 797–801.

2019 Nov;24(11):e1034-e1043. Capecitabine-induced cardiotoxicity is a rare condition that may lead to diagnostic and therapeutic dilemmas.

<> <> 3 0 obj 2008 Jan;134(1):75-82. doi: 10.1007/s00432-007-0250-9. The distribution of the different manifestations of cardiotoxicity. Metabolic Considerations, <>/ProcSet[/PDF/Text/ImageB/ImageC/ImageI] >>/Annots[ 13 0 R] /MediaBox[ 0 0 595.32 841.92] /Contents 4 0 R/Group<>/Tabs/S>>

Patients with more than one of the manifestations (n=2) are classified according to their primary symptom. The percentages showed on each bar reflect the distribution of symptoms among the 22 patients with cardiotoxicity. Clipboard, Search History, and several other advanced features are temporarily unavailable. Fluoropyrimidine chemotherapy has been a standard therapy in a range of solid tumours for … Capecitabine is a type of chemotherapy called an anti metabolite. Kwakman JJ, Simkens LH, Mol L, Kok WE, Koopman M, Punt CJ.Eur J Cancer. 2 0 obj For permission to use (where not already granted under a licence) please go to http://www.bmj.com/company/products-services/rights-and-licensing/. Objectives: Case reports of capecitabine cardiotoxicity resemble those seen with intravenous 5-fluorouracil (5-FU) with chest pain as the predominant manifestation, but few studies of capecitabine cardiotoxicity are available. Capecitabine has a well-documented safety profile; the most commonly reported side effects are hand–foot syndrome (17%), diarrhea (17%), and nausea (15%), but all these toxicities are usually manageable and reversible.

Cardiotoxicity has been associated with fluoropyrimidine therapy, including myocardial infarction, angina, dysrhythmias, cardiogenic shock, sudden death and electrocardiographic changes (including very rare cases of QT prolongation).
These adverse reactions may be more common in patients with a prior history of coronary artery disease. Capecitabine cardiotoxicity cases occurred after 3 days and 6 days of treatment. (Neth Heart J 2009;17:277–80.) In recent years, the incidence of this side effect has increased and it is expected to further rise due to the population aging and the disproportionate incidence of breast and gastrointestinal cancers in older individuals.

Ann Oncol 2002; 13: 797–801. If you do not receive an email within 10 minutes, your email address may not be registered, endobj